|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.
|
16542464 |
2006 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India.
|
18330937 |
2008 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
BEFREE |
For glandular lesions, 6 of 10 (60%) AC from high-risk area and 15 of 20 (75%) from low-risk area showed positive COX-2 staining, and 12 of 17 (70%) premalignant Barrett's esophagus were also positive.
|
12893070 |
2003 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.
|
17006983 |
2006 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We have previously described an association between colorectal adenomas and SNP V102V in PTGS2 and have now confirmed this association for colorectal adenocarcinomas.
|
16482563 |
2006 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
|
18349295 |
2008 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
|
16521222 |
2006 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
RGD |
COX-2 may play an important role in esophageal carcinogenesis through the activation of the inflammation-metaplasia-adenocarcinoma sequence.
|
17675820 |
2007 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Our data suggest that in addition to COX-2, EP2 and EP4 receptors could be a selective target in the prevention and/or treatment of the Barrett's-associated adenocarcinoma.
|
19843025 |
2010 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Moreover, immunohistochemical analysis using serial sections of human colon adenocarcinomas revealed a strong positive correlation between COX-2 and FasL (r=0.722; P<0.0001) expression, and between EP1 receptor and FasL (r=0.740; P<0.0001) expression, in the tumour cells.
|
18648368 |
2008 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
The aim of this study was to evaluate cyclooxygenase-2 (COX-2) immunoreactivity in colorectal adenocarcinomas and to find correlations with different pathological features.
|
25169526 |
2014 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
A longitudinal case-control study compared COX-2 in patients who progressed to adenocarcinoma with nonprogressors matched for age and length of follow-up.
|
15269153 |
2004 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
The association between lymph node metastasis and elevation of COX-2 was stronger in cases of AC than in cases of ASC (28.4 vs. 4.3%, P=0.023).
|
16111807 |
2006 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
COX-2, the inducible isoenzyme, was found to be overexpressed in approximately 85% of colorectal adenocarcinomas, contributing to key steps in tumor development.
|
20075740 |
2010 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Long-term COX-2 inhibition markedly reduced adenocarcinoma formation, as well as angiogenesis in a mouse model of prostate-specific PKCε expression and Pten loss.
|
29765153 |
2018 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
When tumor types were considered, there were more Cox 2-positive adenocarcinomas compared with squamous cell carcinomas (21 of 51 adenocarcinomas [41%] vs. 9 of 46 squamous cell carcinomas [20%]; P = 0.03).
|
11920472 |
2002 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
This study demonstrates a novel relationship between COX-2 expression and the neovasculature of human breast adenocarcinomas.
|
12855643 |
2003 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
|
17581270 |
2007 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
This suggests that Cox-2-derived prostanoids promote aggressive behavior of adenocarcinomas of the stomach.
|
14616542 |
2003 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.
|
11494020 |
2001 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
We studied in mice and human adenocarcinoma-derived Caco-2 cells the impact of low calcium on markers of inflammation (cyclooxygenase-2; COX-2), of detoxification (pregnane and xenobiotic receptor (PXR)/steroid and xenobiotic receptor (SXR), cytochrome P450 steroid-inducible 3a11 (CYP3A11)), and on expression of the vitamin D system as a protection against tumorigenesis.
|
18327873 |
2008 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
The purpose of our study was to characterize the molecular profile of AA and explore the role of targeted therapy against cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR).
|
24149137 |
2013 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n >or= 10 each group) using qRTPCR, single and double immunohistochemistry.
|
19758455 |
2009 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
In the same patient, COX-2 was negative in the hyperplasia region but positive in adenoma and adenocarcinoma regions, showing results reflecting the progression of the disease.
|
11920515 |
2002 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
CTD_human |
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
|
10485483 |
1999 |